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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.005Breast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone receptore
positive, human epidermal growth factor receptor 2epositive (HER2þ), and triple-negative breast
cancer, to guide therapeutic interventions. Agents that target estrogen receptor (ER) and HER2 are
among the most successful cancer therapeutics. However, de novo or acquired resistance is common,
despite the development of newer agents against these pathways. As our understanding of tumor
biology improves, novel targets are being identiﬁed. Notably, inhibitors against several pathways
[including, among others, the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/
mTOR), cell-cycle regulation, heat shock protein, and epigenetic pathways] have demonstrated prom-
ising activity in clinical trials, and the mTOR-inhibitor everolimus has been approved for advanced or
metastatic aromatase inhibitoreresistant ERþ breast cancer. At present, there are no established tar-
geted agents for triple-negative breast cancer (negative ER, progesterone receptor, and HER2).
Although poly(ADP-ribose) polymerase inhibitors have shown promising activity in BRCA-related
cancers, its value in the treatment of triple-negative breast cancers remains to be demonstrated. In
this Review, we present a basic understanding of the major targeted agents in current practice and
under development for the treatment of breast cancer in the context of the three clinical subgroups.
(Am J Pathol 2013, 183: 1096e1112; http://dx.doi.org/10.1016/j.ajpath.2013.07.005)Supported by the Siteman Cancer Center and Foundation for Barnes-
Jewish Hospital, the Susan G. Komen Foundation, and the CALGB Clinical
Investigator Award.
Disclosure: C.X.M. has previously received funding for investigator-
initiated trials from Novartis, Pﬁzer, and Puma.
This article is part of a review series on the molecular pathogenesis of
breast cancer.Estrogen receptor (ER) and human epidermal growth factor
receptor 2 (HER2) are well-established therapeutic targets
and have been the main focus of drug development for the
treatment of breast cancer. A number of hormonal thera-
peutic agents have been approved for the treatment of ERþ
disease, including tamoxifen, aromatase inhibitors (AIs),
and fulvestrant. For HER2þ breast cancer, a growing
number of HER2-targeted agents have become available,
including trastuzumab, lapatinib, pertuzumab, and trastu-
zumab emtansine. However, these agents are ineffective for
triple-negative breast cancers (TNBC). In addition, de novo
or acquired resistance to these agents is common, despite the
presence of ER and HER2. Novel therapeutic targets are
being developed as treatment strategies for TNBC and
resistant ER and HER2þ diseases. In this review, we
discuss major targeted therapies in current practice and
under development for the treatment of hormone receptor-
positive (HRþ) breast cancer, HER2þ breast cancer, and
TNBC.stigative Pathology.
.HRD Breast Cancer
HRþ breast cancers are largely driven by the estrogen/ER
pathway, and endocrine therapy targeting this pathway has
been most successful. However, resistance to endocrine
therapy, either de novo or acquired, is a common phenom-
enon and a signiﬁcant clinical challenge. The mechanisms
of endocrine resistance are complex and not fully under-
stood. Experimental models indicate that endocrine resis-
tance is accompanied by activation of estrogen-independent
growth and survival signaling pathways as a result of
Targeted Therapy for Breast Cancergenomic or epigenetic alterations; these pathways could be
targeted for therapeutic interventions.1 A small fraction of
ERþ breast cancers have ampliﬁcation of the HER2 gene,
ERBB2, and in these cases targeting both ER and HER2 is
necessary.2 Letrozole in combination with lapatinib, a
HER1/2 inhibitor, has been approved as a ﬁrst-line therapy
for metastatic ERþ HER2þ breast cancer. For ERþ HER2
breast cancer, success has been reported with combined
targeting of the phosphoinositide 3-kinase (PI3K) pathway
and ER.3 The mTOR inhibitor everolimus, in combination
with exemestane, has been approved for the treatment of AI-
resistant ERþ metastatic breast cancer. Promising activity
has also been observed in early-phase trials of inhibitors
against cyclin-dependent kinases 4 and 6 (CDK4/6) and
agents that target epigenetic mechanisms.Estrogen Receptor
ER, which belongs to the class of steroid hormonal recep-
tors, plays an important role in cell proliferation, survival,
and invasion of ERþ breast cancer (Figure 1). Binding of
estrogen to ER translocates the cytoplasmic ER to the
nucleus, where estrogen-bound ER forms dimer that func-
tions as a transcription factor via binding to the estrogen
response elements of target genes and the interaction with
coregulators and other transcription factors to activate
downstream gene expression.4 In addition to this classic
genomic action of ER, membrane-associated ER mediates
rapid nongenomic effect through its interactions with
growth factor receptor tyrosine kinases and a variety of
proximal signaling molecules such as G protein, Ras, Src,
and the regulatory subunit of PI3K and Shc, leading to cell
growth and survival signaling activation.The American Journal of Pathology - ajp.amjpathol.orgER-Targeted Therapies and Endocrine Therapy
Endocrine therapy is the mainstay of systemic treatment for
HRþ breast cancer. Various approaches are aimed at either
reducing estrogen level, such as ovarian suppression or
ablation in premenopausal women and AIs in postmeno-
pausal women, or modulating the expression or function of
ER, such as the selective estrogen receptor modulators,
which antagonize the function of ER, and fulvestrant, which
down-regulates ER.
In premenopausal women with metastatic breast cancer,
tamoxifen has efﬁcacy similar to that of ovarian ablation,5
whereas the combination of ovarian suppression plus ta-
moxifen demonstrates a superior disease-free survival (DFS)
and overall survival (OS), compared with ovarian suppres-
sion alone.6 In premenopausal women with early-stage
disease, 5 years of adjuvant tamoxifen reduced the risk of
breast cancer recurrence by 39% [relative risk (RR) for
recurrence Z 0.61; 95% CI Z 0.57e0.65] and the risk of
breast cancer mortality by 30% (RR for deathZ 0.70; 95%
CI Z 0.64e0.75), which translates into a 15-year absolute
reduction of 13% in the risk of recurrence and 9% in the risk
of breast cancer mortality. A recent report of results from the
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS)
trial indicated that 10 years of tamoxifen was associated
with a 25% lower recurrence rate and a 29% lower breast
cancer mortality rate, compared with 5 years of tamoxifen
treatment.7 Although the risk of death from endometrial
cancer was increased from 0.2% to 0.4%, the beneﬁt out-
weighed this risk, which argues for the use of 10 years of
tamoxifen. For patients who become postmenopausal after 5
years of tamoxifen, extended therapy with an AI is another
option, based on the results of the MA17 trial.8 As an
alternative to tamoxifen, ovarian ablation or suppressionFigure 1 ER pathway and mechanisms of
endocrine resistance. Binding of estrogen leads to
activation and dimerization of ER, which trans-
locates to the nucleus and activates target gene
expression via interaction with estrogen response
element (ERE), coactivators, or other transcription
factors. In addition, membrane-bound ER mediates
nongenomic action through its interaction with
growth factor receptor tyrosine kinases or down-
stream molecules. These actions of ER could be
targeted pharmaceutically to treat ERþ breast
cancer.
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Mohamed et alcould be considered as an adjuvant therapy for premeno-
pausal women.
In postmenopausal women, AIs have been shown to
improve OS, compared with tamoxifen, in the metastatic
setting.9 All three AIs [letrozole and anastrozole (nonste-
roidal); exemestane (steroidal)] have shown similar efﬁcacy
in the clinical setting, although nonecross-resistance exists
between the nonsteroidal and the steroidal AIs. Options for
second or later lines of endocrine therapy include another
AI, fulvestrant, tamoxifen, testosterone, megestrol acetate
(Megace), or (paradoxically) estradiol, as well as the re-
cently approved the combination of everolimus and ex-
emestane. In this setting, the higher dose of fulvestrant (500
mg i.m. monthly) is now the approved dose, based on the
result of the Comparison of Faslodex in Recurrent or
Metastatic Breast Cancer (CONFIRM) trial.10 In post-
menopausal women with early-stage disease, multiple large
adjuvant trials have demonstrated that monotherapy with an
AI for 5 years or a switching strategy (from AI to tamoxifen
or from tamoxifen to AI, with a total duration of therapy of
5 years) is superior to tamoxifen (summarized by Rao and
Cobleigh11). The BIG 1-98 trial demonstrated similar efﬁ-
cacy with AI monotherapy or a switching strategy with
tamoxifen.12 Thus, AI has become a preferred approach, or
at least part of the adjuvant hormonal therapy approach, in
postmenopausal women with ERþ breast cancer.
HER2-Targeted Agents in ERþ HER2þ Breast Cancer
The four HER family members [EGFR (alias HER1),
HER2, HER3, and HER4] are tyrosine kinase receptors
important in promoting cell growth and survival. The HER2
gene, ERBB2, is ampliﬁed in approximately 10% of ERþ
breast cancer. Compared with ERþ HER2 disease, ERþ
HER2þ breast cancer is associated with a higher risk of
relapse on adjuvant endocrine therapy. This is explained by
the ﬁnding of incomplete cell-cycle arrest under treatment
with endocrine agents alone in the neoadjuvant setting.13
The beneﬁt of adding HER2-targeted agents in this patient
population was demonstrated in studies of adjuvant trastu-
zumab in HER2þ breast cancer; the ERþ HER2þ subset
derived a signiﬁcant beneﬁt from trastuzumab in reducing
relapse. Thus, adjuvant trastuzumab, in addition to
hormonal therapy, is a standard of care for these patients.
In the metastatic setting, trastuzumab in combination with
anastrozole was associated with a signiﬁcantly longer
progression-free survival (PFS) (4.8 versus 2.4 months) and
a higher clinical beneﬁt rate (CBR) (42.7% versus 20.3%),
compared with anastrozole alone, in patients with metastatic
breast cancer in the phase III Trastuzumab in Dual HER2
ER-Positive Metastatic Breast Cancer (TAnDEM) trial,
although OS was not different.14 In a single-arm trial in
patients with HRþ HER2þ breast cancer, trastuzumab in
combination with letrozole as ﬁrst- or second-line therapy
was associated with an overall response rate (ORR) of 26%
and a CBR of 52%, with 25% of patients experiencing1098durable response that lasted for more than 1 year.15 In
a phase III trial conducted in 1298 postmenopausal women
with metastatic or locally advanced ERþ breast cancer, the
combination of letrozole and lapatinib, a HER1/HER2
kinase inhibitor, was compared with letrozole alone.2 This
study demonstrated a signiﬁcant difference in PFS [8.2
versus 3 months; hazard ratio (HR)Z 0.53e0.96] and ORR
(28% versus 15%; P Z 0.021) favoring the combination
therapy group to letrozole alone2 and leading to the approval
of letrozole and lapatinib combination for the treatment of
advanced ERþ/HER2þ breast cancer.
PI3K-AKT-mTOR Signaling Pathway Inhibitors
The PI3K-AKT-mTOR pathway is a cardinal nodal point in
the transduction of extracellular and intracellular growth and
survival signals (Figure 2). Deregulation of this pathway is an
important mechanism of endocrine resistance.16 Gain-of-
function mutations in the PI3 kinase a catalytic subunit
gene (PIK3CA) occur at a frequency of 30% to 40% and
comprise the most frequent genetic abnormality in ERþ
breast cancer.17 In preclinical models, ERþ breast cancer
carrying PIK3CAmutations was highly dependent on PI3Ka
(alias p110a) for cell survival.18 Knockdown of PIK3CA
using RNAi or inhibition of PI3K or AKT with small-
molecule inhibitors induced apoptosis in the presence of
estrogen deprivation in ERþ breast cancer cell lines.18,19 In
addition, the development of acquired endocrine resistance
was accompanied by activation of the PI3K pathway in
studies of long-term estradiol-deprived breast cancer cell
lines, and inhibition of PI3K pathway signaling reduced
cancer cell growth and survival.19,20
The rapamycin analogs, which are allosteric inhibitors of
mTOR complex 1 through its interaction with FKBP12,
were among the ﬁrst evaluated in clinical trials. The Breast
Cancer Trials of Oral Everolimus-2 (BOLERO-2) trial,
a randomized, double-blind, placebo-controlled phase III
study of exemestane with or without the rapamycin analog
everolimus (Aﬁnitor; Novartis) in postmenopausal women
with ERþ HER2 advanced breast cancer refractory to
nonsteroidal AIs, demonstrated a median PFS of 10.6
months with combination therapy, compared with 4.1
months with exemestane alone (HR Z 0.36; 95% CI Z
0.27e0.47; P < 0.001),3 leading to U.S. Food and Drug
Administration (FDA) approval for its application in the
AI-resistant population. Similarly, the TAMRAD trial,
a randomized phase II study of tamoxifen with or without
everolimus in postmenopausal women with HRþ HER2,
AI-resistant metastatic breast cancer, demonstrated an
improvement in CBR and time to progression (TTP).21
Adjuvant studies of everolimus in combination with
hormonal therapy in early-stage ERþ HER2 breast cancer
are being planned (NCT01805271 and NCT01674140).
The antitumor activity of the rapamycin analogs is likely
hindered by feedback up-regulation of AKT,22 and preclin-
ical studies indicated that perhaps the upstream inhibitors thatajp.amjpathol.org - The American Journal of Pathology
Figure 2 PI3K pathway and inhibitors. Class IA
PI3K is composed of a p85 regulatory domain and
a p110a kinase domain. The inhibitory effect of
p85 on the kinase domain is released after acti-
vation of the tyrosine kinase receptors (RTKs) by
ligand binding. PI3K is also activated by Ras. PI3K
functions to convert the PI(4,5)P2 to PI(3,4,5)P3,
which leads to downstream AKT activation. The
function of PI3K is opposed by the function of
PTEN. PI(3,4)P2, another active phospholipid, is
formed through the action of SHIP-1/2 and inac-
tivated by INPP4B through dephosphorylation.
Agents that target the components of PI3K
pathway are shown.
Targeted Therapy for Breast Cancertarget AKT or PI3K directly would be more effective.18,19 A
number of inhibitors against AKT or PI3K are in clinical trial,
including the pan-PI3K isoform inhibitors, dual PI3K and
mTOR inhibitors, and isoform-speciﬁc inhibitors (Table 1).
The pan-PI3K inhibitor BKM120 (Novartis) is in phase III
trials in combination with fulvestrant in patients with
metastatic ERþ metastatic breast cancer resistant to prior AI
therapy [Buparlisib Breast Cancer Clinical Evaluation 2
(BELLE 2); NCT01610284] or resistant also to an mTOR
inhibitor (BELLE 3; NCT01633060). In addition, an
a-speciﬁc inhibitor of PI3K has shown promising activity
in PIK3CA mutant breast cancer in phase I studies.23 In the
preliminary report of a phase I study of the a-speciﬁc
inhibitor BYL719 (Novartis), 6/18 (33%) patients with
heavily pretreated metastatic breast cancer with PIK3CA
mutation achieved tumor shrinkage >20%, and two of
these six patients achieved a partial response.23 Full results
from these studies are eagerly awaited. A challenge in the
development of these agents has been the inability to
identify the predictors of response in clinical trials, and
prospective studies are needed.
CDK4/6 Inhibitors
The G1-to-S phase transition is controlled by CDKs 4 and 6.
These are activated on binding to D-type cyclins, leading to
phosphorylation of the retinoblastoma susceptibility gene
(RB1) product (Rb), which releases the E2F and DP tran-
scription factors to drive expression from genes promoting
S-phase entry (Figure 3). There is a strong link between the
action of estrogen and CDK4/6 activity, through the tran-
scriptional regulation of cyclin D1 by ER. Persistent cyclinThe American Journal of Pathology - ajp.amjpathol.orgD1 expression and Rb phosphorylation has been associated
with resistance to endocrine therapy in ERþ breast cancer,24
and ERþ breast cancer with genetic aberrations of the cyclin
D1-CDK4/6 pathway is associated with poor clinical
outcomes.17,25 A recent report from the Cancer Genome
Atlas project indicated that the poorer-prognosis luminal
B ERþ diseases are preferentially enriched with gains of
CCND1 (encoding cyclin D1) (58% in luminal B versus
29% in luminal A), and CDK4 (25% in luminal B versus
14% in luminal A) and loss of CDKN2A (encoding p16) and
CDKN2C (encoding p18), which are negative regulators of
CDK4/6.17 Importantly RB1 expression is normal in most
luminal/ERþ breast cancers (unlike in ER disease), a
prerequisite for the activity of CDK4/6 inhibitors. Thus,
CDK4/6 inhibitors are particularly attractive agents for ERþ
disease.
PD 0332991 is a ﬁrst-in-class, oral, highly selective
inhibitor of CDK4/6 kinase (IC50 Z 11 nmol/L; Ki Z 2
nmol/L) with low activity against a panel of 36 additional
protein kinases.26 In a panel of breast cancer cell lines, PD
0332991 was found to be preferentially effective in ERþ
cancer cells, including those that are resistant to anti-
estrogen.25 A synergistic antitumor effect was observed
when PD 0332991 was combined with tamoxifen in both
tamoxifen-sensitive and tamoxifen-resistant cell lines.25 In
a recent report of a randomized phase II study of letrozole
with or without PD 0332991 as ﬁrst-line therapy for meta-
static ERþHER2 breast cancer, a striking improvement was
demonstrated in PFS, from 7.5 to 26.1 months (HRZ 0.37;
95% CIZ 0.21e0.63; P < 0.001), without additional safety
concerns.27 PD 0332991 is currently on the FDA fast-track
list, to accelerate the review and approval process. Two1099
Table 1 Clinical trials of PI3K and AKT inhibitors in breast cancer
Test drug (sponsor)
Trial phase and design
(identiﬁer*) Regimen Population
Panisoform inhibitor of PI3K
XL147 (Sanoﬁ) I/II (NCT01042925) XL147 þ trastuzumab or XL147 þ
paclitaxel þ trastuzumab
Metastatic HER2þ breast cancer
with prior progression on a
trastuzumab-based regimen
I/II (NCT01082068) XL147 þ letrozole Nonsteroidal aromatase inhibitore
resistant ERþ HER2 metastatic
breast cancer
BKM120 (Novartis) II (NCT01629615 and
NCT01790932)
BKM120 Metastatic TNBC
I (NCT01623349) BKM120 þ olaparib TNBC




BKM120 þ trastuzumab þ
paclitaxel vs trastuzumab þ
paclitaxel
Neoadjuvant HER2þ primary breast
cancer
Ib/II (NCT01589861) BKM120 þ lapatinib HER2þ/PI3K-activated, trastuzumab-
resistant metastatic HER2þ breast
cancer






BKM120 þ paclitaxel (BELLE-4) HER2 metastatic breast cancer




BKM120 þ fulvestrant (BELLE-2) Aromatase inhibitoreresistant ERþ




BKM120 þ fulvestrant (BELLE-3) Aromatase inhibitoreresistant ERþ
HER2 metastatic breast cancer
progressed on prior aﬁnitor
Ib (NCT01248494) BKM120 þ endocrine therapy ERþ metastatic breast cancer
Ib (NCT01300962) BKM120 þ capecitabine Metastatic breast cancer
GDC-0941 (Genentech) Ib (NCT00960960) GDC-0941 þ paclitaxel 
bevacizumab or trastuzumab
Metastatic breast cancer











GDC-0941 þ fulvestrant vs
fulvestrant
Aromatase inhibitoreresistant
metastatic ERþ breast cancer
BAY 80-6946 (Bayer) I (NCT01411410) BAY þ paclitaxel Expansion cohort in breast cancer
PI3Ka selective inhibitor
BYL719 (Novartis) Ib (NCT01791478) BYL719 þ endocrine therapy Metastatic ERþ
Dual PI3K/mTOR inhibitor




Ib (NCT01285466) BEZ235 þ paclitaxel BEZ235 þ
paclitaxel þ trastuzumab
Metastatic ERþ breast cancer
II (NCT01495247) BEZ235 þ paclitaxel Metastatic HER2 breast cancer
Ib (NCT01300962) BEZ235 þ capecitabine Metastatic breast cancer
Ib (NCT01248494) BEZ235 þ endocrine therapy Metastatic ERþ breast cancer
(table continues)
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Table 1 (continued )
Test drug (sponsor)
Trial phase and design
(identiﬁer*) Regimen Population
XL765 (Sanoﬁ) I/II (NCT01082068) XL765 þ letrozole Aromatase inhibitoreresistant
ERþ metastatic breast cancer
GDC-0980 (Genentech) II, randomized, double-
blind, placebo-controlled
(NCT01437566)
GDC-0980 þ fulvestrant vs
fulvestrant
Aromatase inhibitoreresistant
ERþ metastatic breast cancer




MK2206 (Merck) I (NCT01344031) MK2206 þ anastrozole or
fulvestrant or anastrozole/
fulvestrant
Metastatic ERþ breast cancer
II (NCT01776008) MK2206 þ anastrozole Neoadjuvant clinical stage II or III
ERþ HER2 breast cancer with
PIK3CA mutation
II (NCT01277757) MK2206 Metastatic breast cancer with
PIK3CA mutation or loss of PTEN
II (NCT01319539) MK2206 Presurgical in operable breast cancer
Ib (NCT01281163) MK2206 þ lapatinib Metastatic HER2þ breast cancer
I (NCT00963547) MK2206 þ lapatinib þ
trastuzumab
Metastatic HER2þ breast cancer
*Details available at http://www.clinicaltrials.gov.
BKM120, buparlisib.
Targeted Therapy for Breast Cancerneoadjuvant studies of PD 0332991 in combination with AIs
in patients with clinical stage II or III ERþ HER2 breast
cancer are ongoing (NCT01723774 and NCT01709370).
There is also a phase I study of PD 0332991 in combination
with paclitaxel in metastatic breast cancer, to evaluate the
toxicity and the maximum tolerated dose of this combination
(NCT01320592). Although preclinical studies indicated that
CCND1 ampliﬁcation, loss of CDKN2A (p16), and intactThe American Journal of Pathology - ajp.amjpathol.orgRB1 predict response to PD 0332991, clinical evaluation of
these markers is ongoing.
Histone Deacetylase Inhibitors
Histone deacetylases (HDACs) and histone acetyltransferases
are important epigenetic mechanisms that regulate gene
transcription through alterations in chromatin structures.Figure 3 CDK4/6 and G1-to-S phase transition.
Cell-cycle progression is controlled by CDKs, which
are activated by their interactions with cyclins. The
G1-to-S phase transition is regulated by CDK4/6
kinases through the interaction with cyclin D, which
is a direct target for estrogen or other growth
factors and is frequently ampliﬁed in ERþ breast
cancer. CDK4/6 is negatively regulated by speciﬁc
and universal inhibitors, including p16, p18, p21,
and p27. CDK4/6 phosphorylate Rb, which releases
the E2F transcription factors and activates expres-
sion of genes required for G1-to-S phase transition.
CDK4/6 is pharmacologically inhibited by PD
0332991 (PD991).
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Figure 4 Targeted therapy for HER2þ breast
cancer. Trastuzumab binds the extracellular
domain of HER2. Pertuzumab binds another HER2
domain, preventing dimerization. Trastuzumab
emtansine (T-DM1) allows this thioester-linked
chemotherapeutic to act on microtubules. Tanes-
pimycin inhibits HSP90, causing HER2 conforma-
tion change. Lapatinib is a small-molecule tyrosine
kinase that inhibits HER1 and HER2. Similarly,
neratinib inhibits HER1, HER2, and HER4.
Mohamed et alEpigenetic deregulation of ER and growth factor receptor
pathway components plays an important role in the devel-
opment of endocrine resistance.28 In preclinical models,
HDAC inhibitors down-regulate the transcription level of
ER29 and induce apoptotic cell death.30,31
Early-phase clinical trials of HDAC inhibitors in combi-
nation with hormonal therapy in patients with AI-resistant
breast cancer have shown encouraging results, suggesting
that HDAC inhibition may be an effective strategy to over-
come resistance in ERþ disease. In a phase II trial of vor-
inostat (Zolinza; Merck) in combination with tamoxifen in
patients with ERþ metastatic breast cancer progressed on
prior endocrine therapy (n Z 43), the overall response rate
was 19% and the clinical beneﬁt (deﬁned as stable disease
>24 weeks) was 40%.32 Results were recently reported from
a randomized, double-blind, placebo-controlled phase II
study of exemestane with or without entinostat, an oral
inhibitor of class 1 HDACs, in postmenopausal women with
locally recurrent or metastatic ERþ breast cancer progressed
on treatment with a nonsteroidal AI.33 The study enrolled 130
women; for the group receiving entinostat with exemestane
versus exemestane alone, median PFS was 4.3 versus 2.3
months (HR Z 0.73; 95% CI Z 0.5e1.07; P Z 0.06) and
OS was 28.1 versus 19.8 months (HR Z 0.59; 95% CI Z
0.36e0.97; P Z 0.036). The most common adverse events
were fatigue and neutropenia, but the treatment was generally
considered well tolerated. Prolonged PFS was observed in
the subset of patients treated with combination therapy and
found to have hyperacetylation of protein lysine in the
peripheral blood mononuclear cells. A phase III conﬁrmatory
study of this combination is planned. Other HDAC inhibitors
being evaluated in breast cancer trials include panobinostat
and vorinostat,28 with results pending. In addition, HDAC
inhibitors are being evaluated in TNBC to induce estrogen
receptor expression and endocrine responsiveness.281102Other Pathways of Interest in ERþ Breast Cancer
Other pathways being examined in ERþ breast cancer
include the IGF-1R, FGFR, Src, and mitogen-activated
protein kinase (MAPK) pathways, as well as angiogenic
pathways, with most still in early-phase clinical trials.1
HER2D Breast Cancer
The HER2 protein, encoded by the ERBB2 gene, is one of
four members of the epidermal growth factor receptor
(EGFR) family: EGFR (alias HER1, ErbB1), HER2 (alias
c-ErbB-2; in rodents, Neu), HER3 (alias ErbB3), and
HER4 (ErbB4). HER2 is the preferred dimerization partner
for the other three family members. Hetero- or homo-
dimerization of EGFR family members leads to autophos-
phorylation of the receptor tyrosine residues to initiate
downstream signaling activation for cell growth and
differentiation. Overexpression of HER2 as a result of gene
ampliﬁcation occurs in 18% to 20% of human breast
cancers and is associated with a more aggressive pheno-
type. Introduction of the monoclonal antibody trastuzumab
has led to signiﬁcant improvement in the outcome of this
disease. In addition to trastuzumab, several HER2-targeted
agents, including laptinib, pertuzumab, and trastuzumab
emtansine have been approved for treatment of advanced
HER2þ disease (Figure 4). Furthermore, agents targeting
several molecular pathways implicated in trastuzumab
resistance have shown promising results in early-phase
clinical trials.
Trastuzumab
Trastuzumab (Herceptin; Genentech), a fully humanized
monoclonal antibody against HER2 extracellular domain, isajp.amjpathol.org - The American Journal of Pathology
Targeted Therapy for Breast Cancerapproved for both metastatic and adjuvant therapy for
HER2þ breast cancer. The mechanisms of action of trastu-
zumab are not fully understood, but studies have shown that
trastuzumab functions by antibody-dependent cellular cyto-
toxicity, inhibition of the cleavage of the HER2 extracellular
domain, inhibition of signaling mediated by HER2 through
PI3K, and MAPK cascades. The activities of trastuzumab in
combination with various chemotherapy agents have been
demonstrated in multiple clinical trials. In the pivotal phase
III trial, the addition of trastuzumab to chemotherapy in the
ﬁrst-line setting for metastatic HER2þ breast cancer resulted
in a signiﬁcant improvements in ORR (50% versus 32%),
median TTP (7.4 versus 4.6 months), and median OS (25
versus 20 months).34 In the adjuvant setting, 1 year of tras-
tuzumab started concurrently with chemotherapy [with
a taxane as part of the anthracycline/taxane adjuvant
chemotherapy regimen or with docetaxel (Taxotere; Sanoﬁ)
in combination with carboplatin] or after the completion of
adjuvant chemotherapy, has been shown to dramatically
reduce the risk of relapse by approximately one half and to
reduce the risk of death by one third.35e39 Subsequent data
from the North Central Cancer Treatment Group (NCCTG)
N9831 study demonstrated that administration of trastuzu-
mab concurrent with chemotherapy is preferred.38 At 8 years
of median follow-up of the HERA trial, DFS and OS were
similar between the 1- and 2-year duration in the trastuzumab
treatment arms, conﬁrming 1 year of trastuzumab as the
standard40 (although a small study of 9 weeks of trastuzumab
added to adjuvant chemotherapy also reduced the risk of
recurrence at a similar magnitude41).
Trastuzumab Resistance
Unfortunately, not all patients with HER2þ breast cancer
respond to trastuzumab therapy. Furthermore, in the metastatic
setting, tumors that initially respond to trastuzumab often
develop treatment resistance. Proposed mechanisms of resis-
tance include inability for trastuzumab to bind to its target due
to a truncated HER2 receptor that lacks the extracellular
domain (p95-HER2) or due to steric hindrance by over-
expression of the membrane-associated glycoprotein MUC4,
crosstalk with IGF-1R, increased activity of other HER family
members, activation of PI3K/Akt pathway as a result of
various mechanisms including PTEN deﬁciency, activating
mutations of AKT, or up-regulation of Rac1 (a Ras-like small
GTPase that interferes the trastuzumab-mediated endocytosis
of HER2). These various mechanisms are being explored for
therapeutic strategies to overcome trastuzumab resistance.
Lapatinib
Lapatinib is an orally available small-molecule inhibitor
effective against both HER1 and HER2, although its use has
been limited largely to HER2þ breast cancer. In a random-
ized phase III study of capecitabine with or without lapati-
nib in patients with HER2þ locally advanced or metastaticThe American Journal of Pathology - ajp.amjpathol.orgbreast cancer who had previously received anthracycline,
taxane, and trastuzumab, the combination therapy was
superior in median TTP (8.4 months versus 4.4 months),
compared with capecitabine alone.42 The combination
therapy was commonly associated with diarrhea (60%,
including 12% grade 3), handefoot syndrome (49%), rash
(27%), nausea (44%), vomiting (26%), and fatigue (18%).
There was a trend toward better OS with the combination
therapy, but this did not reach statistical signiﬁcance.43
Although the analysis was confounded by the crossover of
patients from the monotherapy to the combination therapy
arm, this trial led to FDA approval of lapatinib in the
advanced disease setting. Lapatinib has also been shown to
improve TTP when combined with paclitaxel as ﬁrst-line
therapy for patients with metastatic HER2þ breast cancer,
although with a signiﬁcant increase in adverse effects.44
Combined HER2 targeting with lapatinib and trastuzu-
mab has been shown to be effective in the treatment of
trastuzumab-resistant metastatic HER2þ breast cancer. In
a randomized phase III study of lapatinib versus the
combination of lapatinib and trastuzumab in patients with
HER2þ metastatic breast cancer who had disease progres-
sion on prior trastuzumab-based therapy, the combination
was associated with improved PFS (HRZ 0.73; 95% CIZ
0.57e0.93; P Z 0.008) and CBR (24.7% versus 12.4%;
P Z 0.01), as well as a reduction in risk of death by 26%
(median OS, 14 versus 9.5 months; PZ 0.026).45 Based on
this trial, some have adopted this combination strategy in the
clinical practice in patients for whom no chemotherapy is
administered.
The activity of lapatinib and the combination of lapatinib
and trastuzumab observed in the advanced disease setting
led to its further evaluation in patients with early-stage
diseases. The Neoadjuvant Lapatinib and/or Trastuzumab
Treatment Optimization (NeoALTTO) study compared
lapatinib, trastuzumab, and their combination, administered
initially for 6 weeks followed by the addition of weekly
paclitaxel for 12 weeks before surgery,46 with the primary
endpoint of pathological complete response rate (pCR,
deﬁned as absence of invasive tumor cells in the breast).
No major cardiac dysfunction was recorded, but lapatinib-
containing arms recorded an increased grade 3 diar-
rhea and liver-enzyme alterations, compared with the
trastuzumab-alone arm. There was no statistical difference
in the rate of pCR between the single-agent lapatinib arm
[38/154 (24.7%) patients; 95% CI Z 18.1e32.3] and the
trastuzumab arm (difference, 4.8%; 95% CI Z 17.6 to
8.2; P Z 0.34). The pCR rate, however, was signiﬁcantly
higher in the combined lapatinib and trastuzumab arm [78/
152 (51.3%) patients; 95% CI Z 43.1e59.5], compared
with the trastuzumab-alone arm [44/149 (29.5%) patients;
95% CI Z 22.4% to 37.5%), conﬁrming the enhanced
activity with combined HER2-targeted agents.
In the adjuvant setting, the Adjuvant Lapatinib and/or
Trastuzumab Treatment Optimization (ALTTO) trial has
completed accrual. Patients with early-stage HER2þ breast1103
Mohamed et alcancer (node-positive or breast tumor 1 cm) were
randomized to receive trastuzumab for 1 year or lapatinib
for 1 year or trastuzumab followed by lapatinib for a total of
1 year versus trastuzumab in combination with lapatinib for
1 year. The study enrolled 8381 patients in approximately
50 countries during June 2007 and 2011. Based on the
report of the ﬁrst planned interim analysis of the ALTTO
Independent Data Monitoring Committee that the lapatinib-
alone arm was unlikely to meet the prespeciﬁed criteria to
demonstrate noninferiority to trastuzumab alone with
respect to DFS, the leadership of ALTTO announced the
discontinuation of the lapatinib-alone arm on September 9,
2011. Full results of the ALTTO trial are eagerly awaited.
Pertuzumab
Pertuzumab is an anti-HER2 humanized monoclonal anti-
body that binds to subdomain II of the extracellular domain
of HER2, in contrast to trastuzumab, which binds to sub-
domain IV. Binding of pertuzumab inhibits the dimerization
of HER2 with other HER family members (most notably
HER3) and synergizes with trastuzumab in treating HER2þ
breast cancer in both preclinical47 and clinical studies.48 The
phase III Clinical Evaluation of Pertuzumab and Trastuzu-
mab (CLEOPATRA) trial randomized patients with meta-
static HER2þ breast cancer to trastuzumab plus docetaxel,
with or without pertuzumab as ﬁrst-line treatment.48 The
addition of pertuzumab led to a signiﬁcant improvement in
median PFS (18.5 months versus 12.4 months; HRZ 0.62;
95% CI Z 0.51e0.75; P < 0.001). The combination
therapy was generally well tolerated, with the most common
adverse event being diarrhea (64%).
There was no increase in left ventricular systolic
dysfunction. Although data are still maturing for OS anal-
ysis, the interim analysis indicated a strong trend in favor of
pertuzumab group. This trial has led to FDA approval for
pertuzumab in combination with a taxane and trastuzumab
as ﬁrst-line therapy for HER2þ metastatic disease.
In the early-stage disease setting, pertuzumab was shown
to improve the rate of pCR, without signiﬁcantly increasing
the toxicity, when combined with docetaxel and trastuzu-
mab before surgery in the randomized four-arm phase II
NeoSphere trial, which was conducted in patients with
newly diagnosed early-stage HER2þ breast cancer.49 A
signiﬁcantly higher pCR rate was observed for the triplet
therapy: 45.8% (95% CI Z 36.1e55.7), compared with
29.0% (95% CI Z 20.6e38.5; P Z 0.0141) for trastuzu-
mab plus docetaxel, 24.0% (95% CI Z 15.8e33.7; P Z
0.003) for pertuzumab plus docetaxel arm. The pCR rate of
16.8% after the treatment with only the two antibodies to
HER2, without chemotherapy, is striking, indicating that
a subset of HER2þ breast cancer is likely cured with
combined HER2 targeting approach without the use of
chemotherapy. A randomized phase III trial of trastuzumab
and chemotherapy with or without pertuzumab is being
conducted to evaluate the role of pertuzumab in the adjuvant1104setting for patients with early-stage HER2þ breast cancer
(NCT01358877).
Trastuzumab Emtansine
Trastuzumab emtansine (T-DM1) (Kadcyla; Genentech) is
an antibodyedrug conjugate in which trastuzumab is linked
to the microtubule-inhibitory agent mertansine (DM1).50
Based on the results of the EMILIA trial, T-DM1 was
approved by the FDA in February 2013 for the treatment of
patients with HER2þ metastatic breast cancer who had
previously received trastuzumab and a taxane, separately or
in combination. In this highly publicized trial, 991 patients
with HER2þ metastatic breast cancer previously treated
with a taxane and trastuzumab were randomized to therapy
with lapatinib plus capecitabine versus T-DM1. Median PFS
by independent review was 9.6 months with T-DM1,
compared with 6.4 months in the lapatinib plus capecitabine
arm (HR for progression or death from any cause Z 0.65;
95% CI Z 0.55e0.77; P < 0.001). At the second interim
analysis, median OS crossed the stopping boundary for
efﬁcacy, favoring T-DM1 with 30.9 months versus 25.1
months (P < 0.001). T-DM1 was associated with a higher
ORR (43.6% versus 30.8%; P < 0.001), and lower toxicities
of grade 3 or above, compared with lapatinib plus capeci-
tabine. The most common grade 3 or 4 AEs associated with
T-DM1 are thrombocytopenia (12.9%), elevated AST (4.3%),
and ALT (2.9%). In addition, T-DM1 did not appear to be
associated with an increased cardiac risk.
Investigational Agents for HER2þ Breast Cancer
Neratinib
Neratinib is an orally available pan-HER irreversible tyro-
sine kinase inhibitor. A phase II trial of neratinib in patients
with metastatic HER2þ breast cancer demonstrated a 16-
week PFS of 59% in those with prior trastuzumab therapy
and 78% in patients with no prior trastuzumab treatment,
with median PFS of 22.3 and 39.6, respectively.51 The most
common adverse effect was diarrhea, but this was manage-
able with antidiarrheal agents and dose reductions. A
randomized phase III trial comparing the combination of
neratinib plus capecitabine against the combination of lapa-
tinib plus capecitabine in patients with HER2þ metastatic
breast cancer who have received two or more prior HER2-
directed regimens in the metastatic setting is being con-
ducted (NCT01808573). In addition, a phase II trial of
neratinib in patients with metastatic HER2þ breast cancer
and progressive brain metastasis with the primary objective
of ORR in the central nervous system is being conducted to
investigate its potential for central nervous system metastasis
(NCT01494662). In the subset of patients who are candidates
for craniotomy, tissue neratinib concentration is assessed
from craniotomy specimens, cerebrospinal ﬂuid, and plasma.
In addition, neratinib is being evaluated in a phase II trial in
patients with ERBB2 mutant but nonampliﬁed metastaticajp.amjpathol.org - The American Journal of Pathology
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(NCT01670877). Neratinib is further discussed below, in the
section on somatic ERBB2 mutation without ampliﬁcation.
HSP90 Inhibitors
Heat shock protein 90 (HSP90) is a molecular chaperone
important for the proper folding and conformational stability
of a variety of client proteins, including HER2 and p95-
HER2, that are important in the oncogenic process of cancer
cells. In preclinical models, inhibition of HSP90 leads to
degradation of HER2 and p95-HER2, tumor cell apoptosis,
and growth inhibition.52 In a phase I trial of trastuzumab in
combination with the HSP90 inhibitor alvespimycin (17-
DMAG), one conﬁrmed partial response was observed,
and seven cases of stable disease (lasting 4, 5, 6, 7, 8, 9, and
10 months), in 21 patients with heavily pretreated metastatic
HER2þ breast cancer.53 A phase II trial of the HSP90
inhibitor tanespimycin (17-AAG) in combination with
trastuzumab was conducted in patients with HER2þ meta-
static breast cancer after progression on trastuzumab. This
trial enrolled 31 patients, with a primary endpoint of
response rate according to Response Evaluation Criteria in
Solid Tumors (RECIST) criteria. The ORR was 22%, and
the median PFS was 6 months (95% CIZ 4 to 9 months),54
demonstrating a proof of concept that HSP90 inhibitors are
effective agents for HER2þ breast cancer. Unfortunately,
tanespimycin was suspended for further clinical develop-
ment. Other novel heat shock protein inhibitors are in
clinical development, and results are eagerly awaited.55
PI3K Pathway Inhibition
PI3K pathway activation is an important mechanism of
treatment resistance to trastuzumab.56 Several studies have
shown promising results with agents that target the PI3K
pathway in HER2þ breast cancer. In a pooled analysis of
two small studies of the mTOR inhibitor everolimus in
combination with trastuzumab in metastatic HER2þ breast
cancer that progressed on previous trastuzumab-based
therapy, a partial response rate of 15%, CBR [calculated
as partial response þ complete response þ persistent stable
disease (6 months)] of 34%, and a median PFS of 4.1
months were observed.57 The combination of everolimus
with weekly trastuzumab and paclitaxel yielded an ORR of
44% and an overall disease control rate (6 months) of 74%
in a phase I study of this regimen in a heavily pretreated
HER2þ metastatic breast cancer population.58 In a phase Ib
trial of everolimus in combination with trastuzumab and
vinorelbine in patients with HER2þ metastatic breast cancer
previously treated with trastuzumab, an ORR of 19.1% with
a disease control rate of 83.0% and median PFS of 30.7
weeks was observed in this heavily pretreated patient pop-
ulation.59 These encouraging results led to subsequent phase
III trials evaluating the combination of everolimus and
trastuzumab with paclitaxel in the ﬁrst-line setting
(BOLERO-1; NCT00876395), and with vinorelbine in theThe American Journal of Pathology - ajp.amjpathol.orgsecond- or third-line setting (BOLERO-3; NCT01007942)
for the treatment of HER2þ locally advanced or metastatic
breast cancer. Early-phase trials are ongoing that evaluate
direct PI3K or AKT inhibitors for the treatment of meta-
static HER2þ breast cancer (Table 1).
Somatic ERBB2 Mutation in Breast Cancers
Lacking ERBB2 Ampliﬁcation
A total of 27 somatic mutations in ERBB2 were identiﬁed,
with an incidence of 1.6% (25/1500), in patients with breast
cancer lacking ERBB2 gene ampliﬁcation who participated in
eight breast cancer genome-sequencing projects (summa-
rized by Robert et al60). A majority of these ERBB2 somatic
mutations were found to increase the kinase activity and were
able to induce in vitro cell transformation and xenograft
tumor growth when overexpressed.61 Importantly, these
mutations were sensitive to neratinib, although some were
resistant to lapatinib. Several mutations that cluster in the
extracellular domain were found to be oncogenic and were
sensitive to neratinib in preclinical studies.62 These studies
indicate that somatic mutation is an alternative mechanism to
ERBB2 gene ampliﬁcation in activating HER2 in breast
cancer. A prospective, multi-institutional phase II trial of
neratinib in metastatic ERBB2 mutant but nonampliﬁed
breast cancers has been launched to evaluate the efﬁcacy of
neratinib in this patient population (NCT01670877).
TNBC
Triple-negative breast cancer is a phenotypic description of
breast cancers that do not express ER and progesterone
receptor and are also without HER2 overexpression or
ampliﬁcation. Unlike ERþ or HER2þ breast cancers, there
is no approved targeted therapy for TNBC. Although some
TNBCs are cured with standard surgery and adjuvant
therapy, those with chemoresistant disease tend to have an
aggressive clinical course, manifested as early and visceral
relapses. Intense effort has been devoted to identiﬁcation of
novel therapeutic targets for TNBC; however, the molecular
heterogeneity and complex biology of TNBC pose signiﬁ-
cant challenges to development of targeted agents. Some
progress has been made in classifying TNBC into subtypes
with differing gene expression proﬁles,63,64 but the thera-
peutic implications are yet to be elucidated. Pathways and
agents being examined in clinical trials include anti-
angiogenic agents, EGFR, and PARP inhibitors, as well as
PI3K, Src, and CDKs.
Antiangiogenic Agents
Angiogenesis is an essential step for tumor growth and
metastasis, and vascular endothelial growth factors (VEGFs),
particularly VEGF-A, are among the most prominent factors
in inducing pathological angiogenesis.65 Compared with1105
Mohamed et alother breast cancer subtypes, TNBC has been associated
with signiﬁcantly higher levels of intratumor VEGF-A
expression,66 which provides a rationale for evaluation of
anti-VEGF agents in the treatment of TNBC, even though
these agents are not necessarily classiﬁed as bona ﬁde tar-
geted therapeutics. Bevacizumab (Avastin; Genentech) is
a humanized monoclonal antibody directed against VEGF-A.
In initial studies of bevacizumab in breast cancer, performed
in unselected patients with metastatic HER2 disease, the
addition of bevacizumab to standard chemotherapy improved
ORR and PFS, but not OS.60,67e69 Three randomized,
placebo-controlled phase III trials of bevacizumab were
conducted in the ﬁrst-line metastatic setting: the E2100 trial
(with paclitaxel),67 the Avado trial (with docetaxel),68 and
the Ribbon 1 trial (with an anthracycline-, taxane-, or
capecitabine-based regimen).60 In the subgroup analysis
within each individual trial, patients with TNBC had
considerable improvement in ORR and PFS in the E2100 and
the Avado trials,67,68 but no signiﬁcant improvement was
observed in the Ribbon 1 trial.60 A meta-analysis was per-
formed that included 621 patients with TNBC enrolled in
these three trials (chemotherapy alone, n Z 258; chemo-
therapy in combination with bevacizumab, n Z 363). A
signiﬁcant improvement was observed in PFS (8.1 months
versus 5.4 months; HRZ 0.65; P< 0.0001) and ORR (42%
versus 23%; P < 0.0001) with the combination therapy;
however, no OS beneﬁt was observed (17.5 versus 18.9
months).70
The Ribbon 2 trial investigated the combination of bev-
acizumab with the physician’s choice of either capecitabine,
a taxane (paclitaxel, nab-paclitaxel, or docetaxel), gemcita-
bine, or vinorelbine as second-line treatment for metastatic
HER2 breast cancer; this trial demonstrated an improvement
in PFS, but not OS.69 In the subgroup analysis of 159 patients
with TNBC, comparedwith chemotherapy alone, the addition
of bevacizumab signiﬁcantly improved ORR (41% versus
18%; PZ 0.0078) and PFS (6.0 months versus 2.7 months;
HRZ 0.494; 95%CIZ 0.33e0.74; PZ 0.0006). There was
a trend toward improvedOS (17.9 versus 12.6months; HRZ
0.624; 95% CIZ 0.39e1.007; PZ 0.0534).71
In the neoadjuvant setting, randomized studies of bev-
acizumab in combination with chemotherapy have yielded
conﬂicting results. In the GeparQuinto trial (nZ 1948), the
rate of pCR was signiﬁcantly higher with the addition of
bevacizumab to the epirubicin plus cyclophosphamide fol-
lowed by docetaxel regimen (14.9% versus 18.4%; odds ratio
with addition of bevacizumab, 1.29; 95% CIZ 1.02e1.65;
P Z 0.04).72 The beneﬁt was restricted to the TNBC
subpopulation (n Z 663; pCR rate, 27.9% versus 39.3%;
P Z 0.003), compared with a pCR rate of 7.7% and 7.8%
with and without the addition of bevacizumab, respectively,
among 1262 patients with HRþ tumors (P Z 1.00).
However, these ﬁndings were not reproduced in the NSABP
B-40 trial.73 Although adding bevacizumab to gemcitabinee
docetaxel chemotherapy signiﬁcantly improved the rate of
pCR (28.2% without bevacizumab versus 34.5% with1106bevacizumab; PZ 0.02) in the population overall, the effect
of bevacizumab was more pronounced in the HRþ subset
(15.1% without bevacizumab versus 23.2% with bev-
acizumab; PZ 0.007) than in the HR subset (47.1%without
bevacizumab versus 51.5% with bevacizumab; PZ 0.34).
Preliminary data were recently reported from the phase III
Bevacizumab Adjuvant Therapy in Triple-Negative Breast
Cancer (BEATRICE) trial, which randomized 2591 patients
with TNBC to standard adjuvant chemotherapy with or
without bevacizumab in the adjuvant setting.74 There was no
difference in the primary endpoint, invasive disease-free
survival, between the two treatment arms. Compared with
those in the chemotherapy-alone arm, patients in the bev-
acizumab arm had a higher incidence of grade 3 hypertension
in the combination therapy arm (7% during the chemotherapy
phase and 5% during the bevacizumab maintenance phase,
compared with less than 1% in the chemotherapy-alone arm),
proteinuria (2% during the maintenance phase), congestive
heart failure, and left ventricular dysfunction.
The TNBC subgroup, treatment schedule, and ﬁndings
for these seven studies targeting VEGFs are summarized in
Table 2.
The lack of a positive effect of bevacizumab in TNBC
underscores the need to better understand predictive bio-
markers. Biomarker analyses from the AVADO trial identi-
ﬁed that high plasmaVEGF-A andVEGFR-2 at baselinewere
associated with a greater PFS beneﬁt from bevacizumab.75
Similar ﬁndings were reported from the AVEREL trial of
bevacizumab in combination with trastuzumab and docetaxel
in metastatic HER2þ breast cancer.76 The validity of VEGF-
A level as a predictive biomarker of bevacizumab beneﬁt is
being examined in a prospective trial (MERiDiAN,
GO25632; NCT01663727) in which patients are stratiﬁed
based on baseline plasma VEGF-A concentrations before
randomization to weekly paclitaxel in combination with
either bevacizumab or placebo.
Sunitinib and sorafenib are multitargeted inhibitors of
receptor tyrosines, including VEGFR. In phase III studies,
single-agent sunitinib was inferior to capecitabine in previ-
ously treated metastatic HER2 breast cancer.77 In addition,
sunitinib failed to improve PFS when combined with
docetaxel in the ﬁrst-line setting78 or with capecitabine in
previously treated metastatic HER2 breast cancer.79 In
patients with metastatic TNBC, single-agent sunitinib led to
a worse PFS than standard care in a phase II study.80
Fewer studies have been performed for sorafenib for
metastatic breast cancer. In a randomized, double-blind,
placebo-controlled phase IIb trial in patients with locally
advanced or metastatic HER2 breast cancer, the addition of
sorafenib to capecitabine resulted in a signiﬁcant improve-
ment in PFS, compared with placebo (median, 6.4 versus
4.1 months; HR Z 0.58; 95% CI Z 0.41e0.81; P Z
0.001), with sorafenib favored across subgroups, including
ﬁrst-line (HR Z 0.50; 95% CI Z 0.30e0.82) and second-
line (HR Z 0.65; 95% CI Z 0.41e1.04) treatment.81
Conﬁrmation in phase III trials is needed.ajp.amjpathol.org - The American Journal of Pathology
Table 2 Studies Targeting VEGF in TNBC
Study (setting) TNBC subgroup size Treatment schedule Results in TNBC subgroup
E2100 (1st-line
metastatic)67
n Z 233 Paclitaxel D1, D8, and D15, q4w
Paclitaxel D1, D8, and D15, q4w þ bevacizumab 10 mg/kg
D1 and D15, q4w




n Z 163 1. Docetaxel þ placebo, q3w*
2. Docetaxel þ bevacizumab 7.5 mg/kg, q3w*
3. Docetaxel þ bevacizumab 15 mg/kg, q3w*




n Z 142 Capecitabine-based chemotherapy  bevacizumab
vs placebo
PFS Z 4.2 vs 6.1 months,z
HR Z 0.72
n Z 137 Taxane- or anthracycline-based chemotherapy 
bevacizumab vs placebo




n Z 159 Capecitabine-,taxane-, gemcitabine-, or vinorelbine-based
chemotherapy þ bevacizumab or placebo




n Z 684 Epirubicin þ cyclophosphamide  4 cycles. Docetaxel 
4 cycles
pCR Z 27.8% vs 36.4%,
P Z 0.02
Epirubicin þ cyclophosphamide  4 cycles. Docetaxel þ
bevacizumab  4 cycles
NSABP B-40
(neoadjuvant)73
n Z 479 Taxane-based combinations with capecitabine or
gemcitabine  bevacizumab vs placebo
pCR Z 51.3% vs 47.3%,
P Z 0.44
BEATRICE (adjuvant)74 n Z 2591 Clinician choice chemotherapy þ bevacizumab vs placebo 3-year IDFS Z 83.7% vs
82.7%, P Z 0.18
*Nine cycles maximum.
yResults are for the docetaxel þ bevacizumab 15 mg/kg arm.
zPlacebo vs bevacizumab.
Dn, day n; IDFS, invasive diseaseefree survival; pCR, pathologic complete remission; PFS, progression-free survival; qnw, every n weeks.
Targeted Therapy for Breast CancerTargeting EGFR
Most basal-like breast cancers, the major molecular subtype
of TNBC, overexpress EGFR,82 raising the possibility of
targeting EGFR in TNBC. However, limited phase II trials of
EGFR-targeted agents in TNBC have not demonstrated
signiﬁcant effect. In a phase II study that evaluated weekly
irinotecan plus carboplatin with or without cetuximab as ﬁrst-
or second-line therapy in patients with metastatic breast
cancer, the addition of cetuximab led to an improved
response rate (30% versus 49%), but without any beneﬁt in
PFS and OS among patients with TNBC.83 The TBCRC 001
study evaluated cetuximab alone followed by the addition of
carboplatin at progression versus the combination therapy
from the start in patients with metastatic TNBC.84 The RR
was 6% to cetuximab alone, 16% to cetuximab plus carbo-
platin after progression, and 17% to the cetuximab plus
carboplatin started at the beginning; however, TTP and OS
were short, at 2.1 months (95% CIZ 1.8 to 5.5 months) and
10.4 months (95% CI Z 7.7 to 13.1 months), respectively,
despite combination therapy. Although most TNBCs had
activated EGFR signaling, only a few demonstrated pathway
inhibition after cetuximab treatment. In another study, the
BALI-1 trial, addition of cetuximab to cisplatin improved
PFS (3.7 months versus 1.5 months; HRZ 0.67; PZ 0.03)
and increased RR (20% versus 10.3%; P Z 0.11), but the
study failed to reach the primary objective.85
In regards to EGFR tyrosine kinase inhibitors, neither
geﬁtinib nor erlotinib showed promise in the metastatic and
locally advanced disease setting.86e89 Additional trials areThe American Journal of Pathology - ajp.amjpathol.orgongoing to evaluate erlotinib plus chemotherapy in the neo-
adjuvant setting (NCT00491816) and geﬁtinib in EGFRþ
metastatic TNBC (NCT01732276).
PARP Inhibitors
The poly(ADP-ribose) polymerases (PARPs) are a group of
enzymes important in many cellular processes, including
base excision repair of single-strand DNA breaks, a vital
mechanism for DNA damage repair when homologous
recombination repair mechanisms such as BRCA1/2 are
deﬁcient. PARP inhibitors induced synthetic lethality in
BRCA1- and BRCA2-related tumors in preclinical studies.90
In a phase II trial of olaparib (AZD2281; AstraZeneca) in
metastatic breast cancers in carriers of BRCA mutations, an
ORR of 41% was observed with a 400 mg b.i.d. dose.91
Basal-like breast cancers often demonstrate what can be
termed BRCAness: traits that are shared with those occurring
in BRCA1 or BRCA2 mutation carriers.92 For example,
BRCA1-related breast cancers are commonly high grade,
triple negative, and clustered within the basal-like sporadic
cancers according to gene expression proﬁling. In addition,
both sporadic basal-like and BRCA1-related breast cancers
have a high rate of TP53 mutation and extreme genomic
instability. However, the beneﬁt of PARP inhibitors has not
been proven in unselected TNBC populations. In a phase II,
multicenter, open-label study of olaparib in patients with
recurrent high-grade serous or poorly differentiated ovarian
carcinoma or TNBC, none of the 26 breast cancer patients
(11 known BRCA mutation carriers and 15 TNBC patients1107
Mohamed et alwithout BRCA mutation or with BRCA status unknown) met
RECIST response criteria.93 Another study with an olaparibe
paclitaxel combination in TNBC could not achieve accept-
able dose intensity because of myelosuppression.94 Initially
considered to be an irreversible PARP inhibitor, iniparib in
combination with gemcitabine and carboplatin demon-
strated an improvement in median PFS (5.9 versus 3.6
months; P Z 0.01) and OS (12.3 versus 7.7 months; P Z
0.01), compared with chemotherapy alone, in a phase II
study in patients with metastatic TNBC.95 However, these
results could not be conﬁrmed in the subsequent phase III
trial of the same regimen.96 In addition, it was later
discovered that the primary mechanism of action was not
via PARP inhibition but by nonselective modiﬁcation of
cysteine-containing proteins.97 Other PARP inhibitors under
investigation include veliparib, rucaparib, and niraparib
(MK-4827; Tesaro, Waltham, MA).
Other Pathways of Interest in TNBC
PI3K pathway activation, likely as a result of loss of negative
regulators including PTEN and INPP4B, is frequently
observed in TNBC,17 rendering the PI3K pathway an attrac-
tive therapeutic target. Interestingly, a partial response was
observed in a patient with TNBC treated in a phase I study of
the PI3K inhibitor BKM120.98 BKM120 is currently being
evaluated in phase II trials in patients with metastatic TNBC
(NCT01629615 and NCT01790932). In addition, combina-
tion strategies of PI3K pathway inhibition with PARP
inhibitors (NCT01623349) are being explored in early-phase
clinical trials, based on promising preclinical data.99
Dasatinib, a potent inhibitor of Src family kinases, was
evaluated as a single agent in a phase II study in unselected
patients with advanced TNBC. A response rate of 4.7% was
observed,100 indicating an antitumor effect in a limited subset
of TNBC. Studies investigating predictive biomarkers of
desatinib and combination strategies of desatinib with
chemotherapy agents are underway. Dinaciclib, which is
a potent inhibitor of CDKs 1, 2, 5, and 9, was shown to
induce synthetic lethality in MYC-overexpressing TNBC
cell lines in preclinical studies.101 Dinaciclib is currently
being evaluated in combination with paclitaxel in an early-
phase trial in advanced TNBC (NCT01676753).
In conclusion, there are no established targeted therapies
for TNBC, although PARP inhibitors have shown promising
activity in BRCA-related cancers. With various agents being
evaluated, a common ﬁnding has been that of rare
responders. Despite more detailed subtype analysis of TNBC
by gene expression analysis,63,64 predictive signatures for
targeted agents are lacking.
References
1. Roop RP, Ma CX: Endocrine resistance in breast cancer: molecular
pathways and rational development of targeted therapies. Future
Oncol 2012, 8:273e29211082. Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J,
Johnston S: Lapatinib plus letrozole as ﬁrst-line therapy for HER-2þ
hormone receptor-positive metastatic breast cancer. Oncologist 2010,
15:122e129
3. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS,
Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT,
Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z,
Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in
postmenopausal hormone-receptor-positive advanced breast cancer.
N Engl J Med 2012, 366:520e529
4. Acconcia F, Kumar R: Signaling regulation of genomic and non-
genomic functions of estrogen receptors. Cancer Lett 2006, 238:1e14
5. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J,
Meakin JW, Shelley W, Pritchard KI: An individual patient-based
meta-analysis of tamoxifen versus ovarian ablation as ﬁrst line
endocrine therapy for premenopausal women with metastatic breast
cancer. Breast Cancer Res Treat 1997, 44:201e210
6. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L,
Sylvester R; Combined Hormone Agents Trialists’ Group and the
European Organization for Research and Treatment of Cancer:
Combined tamoxifen and luteinizing hormone-releasing hormone
(LHRH) agonist versus LHRH agonist alone in premenopausal
advanced breast cancer: a meta-analysis of four randomized trials.
J Clin Oncol 2001, 19:343e353
7. Davies C, Pan H, Godwin J, Gray R, Peto R; ATLAS Collabo-
rators Worldwide: ATLASe10 v 5 years of adjuvant tamoxifen
(TAM) in ERþ disease: effects on outcome in the ﬁrst and in the
second decade after diagnosis. Cancer Res 2012, 72(Suppl 3),
(Abstract S1-2)
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ,
Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB,
Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P,
Palmer MJ, Pater JL: A randomized trial of letrozole in post-
menopausal women after ﬁve years of tamoxifen therapy for early-
stage breast cancer. N Engl J Med 2003, 349:1793e1802
9. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP: Survival with aro-
matase inhibitors and inactivators versus standard hormonal therapy
in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006, 98:
1285e1291
10. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN,
Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR,
Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M:
Results of the CONFIRM phase III trial comparing fulvestrant 250
mg with fulvestrant 500 mg in postmenopausal women with
estrogen receptor-positive advanced breast cancer [Erratum
appeared in J Clin Oncol 2011, 29:229]. J Clin Oncol 2010, 28:
4594e4600
11. Rao RD, Cobleigh MA: Adjuvant endocrine therapy for breast
cancer. Oncology (Williston Park) 2012, 26:541e547
12. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B,
Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M,
Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collab-
orative Group; International Breast Cancer Study Group (IBCSG):
Assessment of letrozole and tamoxifen alone and in sequence for
postmenopausal women with steroid hormone receptor-positive
breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years
median follow-up. Lancet Oncol 2011, 12:1101e1108
13. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L,
Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR,
Dixon JM: Estrogen-independent proliferation is present in estrogen-
receptor HER2-positive primary breast cancer after neoadjuvant
letrozole. J Clin Oncol 2006, 24:3019e3025
14. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A,
Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C,
Jones A: Trastuzumab plus anastrozole versus anastrozole alone for
the treatment of postmenopausal women with human epidermal
growth factor receptor 2-positive, hormone receptor-positiveajp.amjpathol.org - The American Journal of Pathology
Targeted Therapy for Breast Cancermetastatic breast cancer: results from the randomized phase III
TAnDEM study. J Clin Oncol 2009, 27:5529e5537
15. Marcom PK, Isaacs C, Harris L, Wong Z, Kommarreddy A,
Novielli N, Mann G, Tao Y, Ellis M: The combination of letrozole
and trastuzumab as ﬁrst or second-line biological therapy produces
durable responses in a subset of HER2 positive and ER positive
advanced breast cancers. Breast Cancer Res Treat 2007, 102:43e49
16. Ma CX, Crowder RJ, Ellis MJ: Importance of PI3-kinase pathway in
response/resistance to aromatase inhibitors. Steroids 2011, 76:
750e752
17. Cancer Genome Atlas Network: Comprehensive molecular portraits
of human breast tumours. Nature 2012, 490:61e70
18. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM,
Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR,
Olson JA Jr., Watson MA, Saporita A, Weber JD, Ellis MJ: PIK3CA
and PIK3CB inhibition produce synthetic lethality when combined
with estrogen deprivation in estrogen receptor-positive breast cancer.
Cancer Res 2009, 69:3955e3962
19. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F,
Lin L, Ellis MJ: Preclinical modeling of combined phosphatidylino-
sitol-3-kinase inhibition with endocrine therapy for estrogen receptor-
positive breast cancer. Breast Cancer Res 2011, 13:R21
20. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB,
Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL:
Hyperactivation of phosphatidylinositol-3 kinase promotes escape
from hormone dependence in estrogen receptor-positive human breast
cancer. J Clin Invest 2010, 120:2406e2413
21. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM,
Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D,
Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E:
Randomized phase II trial of everolimus in combination with
tamoxifen in patients with hormone receptor-positive, human
epidermal growth factor receptor 2-negative metastatic breast cancer
with prior exposure to aromatase inhibitors: a GINECO study. J Clin
Oncol 2012, 30:2718e2724
22. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H,
Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR
inhibition induces upstream receptor tyrosine kinase signaling and
activates Akt. Cancer Res 2006, 66:1500e1508
23. Juric D, Argiles G, Burris HA, Gonzalez-Angulo AM, Saura C,
Quadt C, Douglas M, Demanse D, De Buck S, Baselga J: Phase I
study of BYL719, an alpha-speciﬁc PI3K inhibitor, in patients with
PIK3CA mutant advanced solid tumors: preliminary efﬁcacy and
safety in patients with PIK3CA mutant ER-positive (ERþ) metastatic
breast cancer (MBC). Cancer Res 2012, 72(Suppl 3). Abstract P6-
10-07
24. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM,
Witkiewicz AK, Clarke R, Knudsen ES: Therapeutically activating
RB: reestablishing cell cycle control in endocrine therapy-resistant
breast cancer. Endocr Relat Cancer 2011, 18:333e345
25. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ,
Ginther C, Ateﬁ M, Chen I, Fowst C, Los G, Slamon DJ: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res 2009, 11:R77
26. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E,
Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL:
Speciﬁc inhibition of cyclin-dependent kinase 4/6 by PD 0332991
and associated antitumor activity in human tumor xenografts. Mol
Cancer Ther 2004, 3:1427e1438
27. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO,
Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR,
Voytko NL, Breazna A, Kim ST, Randolph S, Slamon DJ: Results of
a randomized phase 2 study of PD 0332991, a cyclin-dependent
kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letro-
zole alone for ﬁrst-line treatment of ERþ/HER2 advanced breast
cancer (BC). Cancer Res 2012, 72(Suppl 3). Abstract S1-6The American Journal of Pathology - ajp.amjpathol.org28. Pathiraja TN, Stearns V, Oesterreich S: Epigenetic regulation in
estrogen receptor positive breast cancererole in treatment response.
J Mammary Gland Biol Neoplasia 2010, 15:35e47
29. Yi X, Wei W, Wang SY, Du ZY, Xu YJ, Yu XD: Histone deacetylase
inhibitor SAHA induces ERalpha degradation in breast cancer MCF-
7 cells by CHIP-mediated ubiquitin pathway and inhibits survival
signaling. Biochem Pharmacol 2008, 75:1697e1705
30. Thomas S, Thurn KT, Biçaku E, Marchion DC, Munster PN: Addi-
tion of a histone deacetylase inhibitor redirects tamoxifen-treated
breast cancer cells into apoptosis, which is opposed by the induc-
tion of autophagy. Breast Cancer Res Treat 2011, 130:437e447
31. Biçaku E, Marchion DC, Schmitt ML, Münster PN: Selective inhi-
bition of histone deacetylase 2 silences progesterone recep-
toremediated signaling. Cancer Res 2008, 68:1513e1519
32. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A,
Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE: A
phase II study of the histone deacetylase inhibitor vorinostat
combined with tamoxifen for the treatment of patients with hormone
therapy-resistant breast cancer. Br J Cancer 2011, 104:1828e1835
33. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M,
Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ,
Trepel JB: Randomized phase II, double-blind, placebo-controlled
study of exemestane with or without entinostat in postmenopausal
women with locally recurrent or metastatic estrogen receptor-positive
breast cancer progressing on treatment with a nonsteroidal aromatase
inhibitor. J Clin Oncol 2013, 31:2128e2135
34. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V,
Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
Baselga J, Norton L: Use of chemotherapy plus a monoclonal anti-
body against HER2 for metastatic breast cancer that overexpresses
HER2. N Engl J Med 2001, 344:783e792
35. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr.,
Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA,
Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG,
Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR,
Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Tras-
tuzumab plus adjuvant chemotherapy for operable HER2-positive
breast cancer. N Engl J Med 2005, 353:1673e1684
36. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A,
UntchM, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D,
Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M,
Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C,
Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C,
McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA)
Trial Study Team: Trastuzumab after adjuvant chemotherapy in
HER2-positive breast cancer. N Engl J Med 2005, 353:1659e1672
37. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M,
Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T,
Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V,
Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A,
Crown J; Breast Cancer International Research Group: Adjuvant
trastuzumab in HER2-positive breast cancer. N Engl J Med 2011,
365:1273e1283
38. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA,
Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-
Aspitia A, Pisansky TM, Jenkins RB: Sequential versus concurrent
trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol
2011, 29:4491e4497
39. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S,
Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D,
Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A,
Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G,
Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin
Adjuvant (HERA) Trial Study Team: Treatment with trastuzumab for
1 year after adjuvant chemotherapy in patients with HER2-positive
early breast cancer: a 4-year follow-up of a randomised controlled
trial. Lancet Oncol 2011, 12:236e2441109
Mohamed et al40. Goldhirsch A, Piccart-Gebhart MJ, Procter M, de Azambuja E,
Weber HA, Untch M, Smith I, Gianni L, Jackisch C, Cameron D,
Bell R, Dowsett M, Gelber RD, Leyland-Jones B, Baselga J; the
HERA Study Team: HERA TRIAL: 2 years versus 1 year of tras-
tuzumab after adjuvant chemotherapy in women with HER2-positive
early breast cancer at 8 years of median follow up. Cancer Res 2012,
72(Suppl 3). Abstract S5-2
41. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T,
Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A,
Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M,
Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M,
Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I,
Isola J; FinHer Study Investigators: Adjuvant docetaxel or vinor-
elbine with or without trastuzumab for breast cancer. N Engl J
Med 2006, 354:809e820
42. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG,
Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B,
Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD,
Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive
advanced breast cancer [Erratum appeared in N Engl J Med 2007,
356:1487]. N Engl J Med 2006, 355:2733e2743
43. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T,
Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J,
Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI,
Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C,
Rubin S, Stein S, Geyer CE: A phase III randomized comparison of
lapatinib plus capecitabine versus capecitabine alone in women with
advanced breast cancer that has progressed on trastuzumab: updated
efﬁcacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:
533e543
44. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J,
Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH,
Williams LS, Dering J, Finn RS, Press MF: Phase III, double-
blind, randomized study comparing lapatinib plus paclitaxel with
placebo plus paclitaxel as ﬁrst-line treatment for metastatic breast
cancer [Erratum appeared in J Clin Oncol 2009, 27:1923]. J Clin
Oncol 2008, 26:5544e5552
45. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G,
Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J,
O’Shaughnessy J: Randomized study of lapatinib alone or in combi-
nation with trastuzumab in women with ErbB2-positive, trastuzumab-
refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124e1130
46. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E,
Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G,
Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J,
Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M,
Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M;
NeoALTTO Study Team: Lapatinib with trastuzumab for HER2-
positive early breast cancer (NeoALTTO): a randomised, open-
label, multicentre, phase 3 trial [Erratum appeared in Lancet 2012,
379:616; dosage error in published abstract; MEDLINE/PubMed
abstract corrected]. Lancet 2012, 379:633e640
47. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J,
Hasmann M: Strongly enhanced antitumor activity of trastuzumab
and pertuzumab combination treatment on HER2-positive human
xenograft tumor models. Cancer Res 2009, 69:9330e9336
48. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L,
Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G,
Swain SM; CLEOPATRA Study Group: Pertuzumab plus trastuzu-
mab plus docetaxel for metastatic breast cancer. N Engl J Med 2012,
366:109e119
49. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC,
Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL,
Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G,
Szado T, Ratnayake J, Ross G, Valagussa P: Efﬁcacy and safety of
neoadjuvant pertuzumab and trastuzumab in women with locally
advanced, inﬂammatory, or early HER2-positive breast cancer1110(NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Lancet Oncol 2012, 13:25e32
50. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J,
Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S,
Blackwell K; EMILIA Study Group: Trastuzumab emtansine for
HER2-positive advanced breast cancer [Erratum appeared in N Engl J
Med 2013, 368:2442]. N Engl J Med 2012, 367:1783e1791
51. BursteinHJ, SunY,Dirix LY, Jiang Z, ParidaensR, TanAR,AwadaA,
Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K,
Vermette J, Zacharchuk C, Badwe R: Neratinib, an irreversible ErbB
receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-
positive breast cancer. J Clin Oncol 2010, 28:1301e1307
52. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M,
Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N:
Inhibitors of HSP90 block p95-HER2 signaling in trastuzumab-
resistant tumors and suppress their growth. Oncogene 2010, 29:
325e334
53. Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A,
Zhong Z, Ma W, Hudis C, Modi S: A phase I dose-escalation trial of
trastuzumab and alvespimycin hydrochloride (KOS-1022; 17
DMAG) in the treatment of advanced solid tumors. Clin Cancer Res
2012, 18:5090e5098
54. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N,
D’Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S,
Norton L, Hannah AL, Hudis C: HSP90 inhibition is effective in breast
cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in
patients with HER2-positive metastatic breast cancer progressing on
trastuzumab. Clinical Cancer Res 2011, 17:5132e5139
55. De Mattos-Arruda L, Cortes J: Breast cancer and HSP90 inhibitors: is
there a role beyond the HER2-positive subtype? Breast 2012, 21:
604e607
56. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM,
Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K,
Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ,
Bernards R: A functional genetic approach identiﬁes the PI3K
pathway as a major determinant of trastuzumab resistance in breast
cancer. Cancer Cell 2007, 12:395e402
57. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR,
Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J,
Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ: Phase I/II
study of trastuzumab in combination with everolimus (RAD001) in
patients with HER2-overexpressing metastatic breast cancer who
progressed on trastuzumab-based therapy. J Clin Oncol 2011, 29:
3126e3132
58. Andre F, Campone M, O’Regan R, Manlius C, Massacesi C,
Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA:
Phase I study of everolimus plus weekly paclitaxel and trastuzumab
in patients with metastatic breast cancer pretreated with trastuzumab.
J Clin Oncol 2010, 28:5110e5115
59. Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L,
Zhang Y, Massacesi C, Sahmoud T, Gianni L: Phase I trial of oral
mTOR inhibitor everolimus in combination with trastuzumab and
vinorelbine in pre-treated patients with HER2-overexpressing meta-
static breast cancer. Breast Cancer Res Treat 2011, 125:447e455
60. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I,
Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC,
O’Shaughnessy J: RIBBON-1: randomized, double-blind, placebo-
controlled, phase III trial of chemotherapy with or without bev-
acizumab for ﬁrst-line treatment of human epidermal growth factor
receptor 2-negative, locally recurrent or metastatic breast cancer. J
Clin Oncol 2011, 29:1252e1260
61. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC,
Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER,
Ellis MJ: Activating HER2 mutations in HER2 gene ampliﬁcation
negative breast cancer. Cancer Discov 2013, 3:224e237
62. Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka K, Yun CH,
Imielinski M, Banerji S, Lawrence MS, Walker S, Winckler W,ajp.amjpathol.org - The American Journal of Pathology
Targeted Therapy for Breast CancerGetz G, Frank D, Eck M, Jaffe JD, Carr SA, Wong KK, Meyerson M:
Oncogenic extracellular domain mutations of ERBB2 in cancer.
Cancer Res 2012, 72(Suppl 1). Abstract 1
63. Criscitiello C, Azim HA Jr., Schouten PC, Linn SC, Sotiriou C:
Understanding the biology of triple-negative breast cancer. Ann
Oncol 2012, 23(Suppl 6):vi13evi18
64. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB,
Shyr Y, Pietenpol JA: Identiﬁcation of human triple-negative breast
cancer subtypes and preclinical models for selection of targeted
therapies. J Clin Invest 2011, 121:2750e2767
65. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its
receptors. Nat Med 2003, 9:669e676
66. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van
Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CGJ,
Klijn JGM: High tumor levels of vascular endothelial growth factor
predict poor response to systemic therapy in advanced breast cancer.
Cancer Res 2001, 61:5407e5414
67. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA,
Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab
versus paclitaxel alone for metastatic breast cancer. N Engl J Med
2007, 357:2666e2676
68. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P,
Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG,
Schneeweiss A, Wardley AM, Chlistalla A, Romieu G: Phase III
study of bevacizumab plus docetaxel compared with placebo plus
docetaxel for the ﬁrst-line treatment of human epidermal growth
factor receptor 2-negative metastatic breast cancer. J Clin Oncol
2010, 28:3239e3247
69. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V,
Rugo HS: RIBBON-2: a randomized, double-blind, placebo-
controlled, phase III trial evaluating the efﬁcacy and safety of
bevacizumab in combination with chemotherapy for second-line
treatment of human epidermal growth factor receptor 2-negative
metastatic breast cancer. J Clin Oncol 2011, 29:4286e4293
70. O’Shaughnessy J, Romieu G, Diéras V, Byrtek M, Duenne AA,
Miles D: Meta-analysis of patients with triple-negative breast cancer
(TNBC) from three randomized trials of ﬁrst-line bevacizumab (BV)
and chemotherapy treatment for metastatic breast cancer (MBC).
Cancer Res 2010, 70(Suppl 2). Abstract P6-12-03
71. Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS,
Rivera R, Duenne A, Bousfoul N, Yardley DA: Second-line
bevacizumab-containing therapy in patients with triple-negative
breast cancer: subgroup analysis of the RIBBON-2 trial. Breast
Cancer Res Treat 2012, 133:1067e1075
72. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H,
Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R,
Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J,
Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S,
Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft
Gynäkologische OnkologieeBreast Study Groups: Neoadjuvant
chemotherapy and bevacizumab for HER2-negative breast cancer. N
Engl J Med 2012, 366:299e309
73. Bear HD, Tang G, Rastogi P, Geyer CE Jr., Robidoux A, Atkins JN,
Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA,
Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM,
Costantino JP, Swain SM, Mamounas EP, Wolmark N: Bevacizumab
added to neoadjuvant chemotherapy for breast cancer. N Engl J Med
2012, 366:310e320
74. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X,
Steger G, Suter T, Toi M, Parmar M, Bubuteishvili-Pacaud L,
Henschel V, Laeuﬂe R, Bell R: Primary results of BEATRICE,
a randomized phase III trial evaluating adjuvant bevacizumab-
containing therapy in triple-negative breast cancer. Cancer Res
2012, 72(Suppl 3). Abstract S6-5
75. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X,
Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ:
Biomarker results from the AVADO phase 3 trial of ﬁrst-lineThe American Journal of Pathology - ajp.amjpathol.orgbevacizumab plus docetaxel for HER2-negative metastatic breast
cancer. Br J Cancer 2013, 108:1052e1060
76. Gianni L, Chan A, Mansutti M, Pivot X, Greil R, Provencher L,
Prot S, Moore N, Scherer SJ, Pallaud C: Biomarker (BM) results from
the phase III AVEREL trial of 1st-line bevacizumab (BV), trastuzu-
mab (H) þ docetaxel (T) for HER2-positive locally recurrent/meta-
static breast cancer (LR/MBC). Ann Oncol 2012, 23(Suppl 9):ix531.
abstract 1657P
77. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T,
Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N,
Brickman MJ, Zhang K, Kern KA, Martin M: Phase III randomized
trial of sunitinib versus capecitabine in patients with previously
treated HER2-negative advanced breast cancer. Breast Cancer Res
Treat 2010, 121:121e131
78. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R,
Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J,
Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C: First-line
treatment of advanced breast cancer with sunitinib in combination
with docetaxel versus docetaxel alone: results of a prospective,
randomized phase III study. J Clin Oncol 2012, 30:921e929
79. Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T,
Davidson N, Wildiers H, Fasching PA, Capitain O, RamosM, Greil R,
Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C,
Kreienberg R, Miller WH Jr., Tassell V, Huang X, Paolini J, Kern KA,
Romieu G: Phase III trial of sunitinib in combination with capecitabine
versus capecitabine monotherapy for the treatment of patients with
pretreated metastatic breast cancer. J Clin Oncol 2013, 31:2870e2878
80. Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R,
Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A:
Randomized phase II study of sunitinib versus standard of care for
patients with previously treated advanced triple-negative breast
cancer. Breast 2013. http://dx.doi.org/10.1016/j.breast.2013.07.037
[Epub ahead of press]
81. Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H,
Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B, Llombart A,
Garicochea B, Durán MÁ, Hoff PM, Espié M, de Moraes AA,
Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S,
Li S, Costa F: Sorafenib in combination with capecitabine: an oral
regimen for patients with HER2-negative locally advanced or meta-
static breast cancer. J Clin Oncol 2012, 30:1484e1491
82. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Her-
nandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA,
Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immu-
nohistochemical and clinical characterization of the basal-like subtype
of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367e5374
83. O’Shaughnessy J, Weckstein DJ, Vukelja SJ, McIntyre K, Krekow L,
Holmes FA, Asmar L, Blum JL: Preliminary results of a randomized
phase II study of weekly irinotecan/carboplatin with or without
cetuximab in patients with metastatic breast cancer. Breast Cancer
Res Treat 2007, 106(Suppl 1):S32eS33
84. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX,
Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC,
Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS,
Hoadley KA, Perou CM,Winer EP: TBCRC 001: randomized phase II
study of cetuximab in combination with carboplatin in stage IV triple-
negative breast cancer. J Clin Oncol 2012, 30:2615e2623
85. Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM,
Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC,
Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A,
Groos J, Melezínková H, Awada A: Randomized phase II study of
the anti-epidermal growth factor receptor monoclonal antibody
cetuximab with cisplatin versus cisplatin alone in patients with
metastatic triple-negative breast cancer. J Clin Oncol 2013, 31:
2586e2592
86. Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A,
Snyder R, Fong A, Basser R, Forbes JF; Australian New Zealand
Breast Cancer Trials Group: Geﬁtinib treatment in hormone-resistant1111
Mohamed et aland hormone receptor-negative advanced breast cancer. Ann Oncol
2009, 20:1813e1817
87. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U,
Luck HJ, Kettner E, Hilfrich J, Eiermann W, Torode J,
Schneeweiss A: A multicentre phase II study on geﬁtinib in taxane-
and anthracycline-pretreated metastatic breast cancer. Breast Cancer
Res Treat 2005, 89:165e172
88. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP: Efﬁ-
cacy and safety of erlotinib in patients with locally advanced or
metastatic breast cancer. Breast Cancer Res Treat 2009, 115:115e121
89. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF,
Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA,
Bromberg JF, Seidman AD, D’Andrea GM, Moasser MM,
Melisko M, Park JW, Dancey J, Norton L, Hudis CA: A phase II trial
of erlotinib in combination with bevacizumab in patients with
metastatic breast cancer. Clin Cancer Res 2008, 14:7878e7883
90. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA,
Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C,
Martin NMB, Jackson SP, Smith GCM, Ashworth A: Targeting the
DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Nature 2005, 434:917e921
91. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW,
Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK,
Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J: Oral
poly(ADP-ribose) polymerase inhibitor olaparib in patients with
BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-
concept trial. Lancet 2010, 376:235e244
92. Turner N, Tutt A, Ashworth A: Hallmarks of ‘BRCAness’ in sporadic
cancers. Nat Rev Cancer 2004, 4:814e819
93. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A,
Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R,
Macpherson E, Carmichael J, Oza A: Olaparib in patients with
recurrent high-grade serous or poorly differentiated ovarian carci-
noma or triple-negative breast cancer: a phase 2, multicentre, open-
label, non-randomised study. Lancet Oncol 2011, 12:852e861
94. Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A,
McCarthy NJ, Singer CF, Lowe ES, Kemsley K, Carmichael J: Safety
and efﬁcacy of the oral PARP inhibitor olaparib (AZD2281) in
combination with paclitaxel for the ﬁrst-or second-line treatment of1112patients with metastatic triple-negative breast cancer: results from the
safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010,
28(Suppl May 20):1018
95. O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C,
Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in
metastatic triple-negative breast cancer. N Engl J Med 2011, 364:
205e214
96. O’Shaughnessy J, Telli M, Swain S, Gralow J, Rugo H, Litton J,
Charpentier E, Smith J, Blackwood-Chirchir A, Winer E: Phase 3
study of iniparib (I) plus gemcitabine (G) and carboplatin (C) in
metastatic triple-negative breast cancer (mTNBC). Results of an
exploratory analysis by prior therapy. Eur J Cancer 2011, 47(Suppl
1):S338. Abstract 5025
97. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA,
Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R,
Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF,
Shoemaker AR: Iniparib nonselectively modiﬁes cysteine-containing
proteins in tumor cells and is not a bona ﬁde PARP inhibitor. Clin
Cancer Res 2012, 18:510e523
98. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D,
Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M,
Baselga J: Phase I, dose-escalation study of BKM120, an oral pan-
class I PI3K inhibitor, in patients with advanced solid tumors.
J Clin Oncol 2012, 30:282e290
99. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J,
Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C,
Pandolﬁ PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM:
Combining a PI3K inhibitor with a PARP inhibitor provides an
effective therapy for BRCA1-related breast cancer. Cancer Discov
2012, 2:1048e1063
100. Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC,
Fairchild J, Sy O, Goldstein LJ: Dasatinib as a single agent in triple-
negative breast cancer: results of an open-label phase 2 study. Clin
Cancer Res 2011, 17:6905e6913
101. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME,
Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW,
Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A: MYC
pathway activation in triple-negative breast cancer is synthetic lethal
with CDK inhibition. J Exp Med 2012, 209:679e696ajp.amjpathol.org - The American Journal of Pathology
